Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. - sprookjes - yvandenbroek - TriplyDB

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.

http://www.wikidata.org/entity/Q37641644

about

Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.Immune Consequences of in vitro Infection of Human Peripheral Blood Leukocytes with Vesicular Stomatitis Virus.Targeting IκappaB kinases for cancer therapy.

P2860

Q38676507-29021E31-1E08-4439-B49F-29DA9158C6E2 Q45324769-737AE983-ECB4-444F-B2D2-C467D3FE0177 Q47121717-48BD2257-0A1C-4A5E-9870-2F38A5C4E097 Q47557500-D9D4CB9F-B221-40E0-8D1F-88D7F7E68E06 Q52372117-7103AE5D-8F45-4F22-B52A-86A530771AA3

P2860

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.

http://www.wikidata.org/entity/Q37641644

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Novel biomarkers of resistance ...... ic vesicular stomatitis virus.

@en

Novel biomarkers of resistance ...... ic vesicular stomatitis virus.

@nl

type

label

Novel biomarkers of resistance ...... ic vesicular stomatitis virus.

@en

Novel biomarkers of resistance ...... ic vesicular stomatitis virus.

@nl

prefLabel

Novel biomarkers of resistance ...... ic vesicular stomatitis virus.

@en

Novel biomarkers of resistance ...... ic vesicular stomatitis virus.

@nl

P1433

Q37641644-03B799CB-635F-46D5-8163-A4EA2E0C5DCF

P1476

Q37641644-71954BB5-4F74-4ECE-B65C-6D3720F37E13

P2093

Q37641644-3C79A084-3BA4-4B4E-AC87-F60134619B23

Q37641644-45DCF467-FB63-42EA-BDC6-39DEA0993D42

Q37641644-602653DD-A1A3-4E47-8C22-D6A8F5BF6A8A

Q37641644-852C51C3-4F8C-411B-BB83-953BE9A6F903

Q37641644-9717AFE0-6B11-4AB6-92A9-0AF272739EE1

Q37641644-E44E4824-BCB6-4181-B954-79DA1902F8DE

P2860

Q37641644-078F6908-D72C-48C9-8A45-A400413C2606

Q37641644-0B6DF27C-2A18-401D-8FBB-C12CDF443DA8

Q37641644-0EB25AAF-990F-4689-923E-79FF78EE36E5

Q37641644-131EF935-74E4-4F3E-96C2-15146CD0AADE

Q37641644-1499EE1E-1BD4-4392-BBFB-D4BE199A9E10

Q37641644-1B4D9767-0BB1-4C15-9AF3-6652F81BCA79

Q37641644-1FFACACD-3FC5-48EF-9E1F-FDE128C7AA47

Q37641644-2026773B-8F0B-4471-9ECD-04D46A6E6FC1

Q37641644-2B0EE608-4681-4A3E-8CE4-77FE11B108F3

Q37641644-2BA3D1A5-7058-47B7-85B0-B8740E6A31AB

P304

Q37641644-6BEA97B2-DF89-4E88-A097-413E789A0413

P31

Q37641644-B0DF3D10-CAEB-4C06-A864-AAFA5BA07402

P356

Q37641644-431ABBEC-4CF2-4611-A073-1F3F52139634

P407

Q37641644-DDE3A9B0-4938-4C35-A13F-CBCB4D4535DD

P433

Q37641644-B7AADD40-16B0-495B-9BB0-97F13070E147

P478

Q37641644-A4867CE5-EEE1-4769-A742-5BEB27C6B746

P577

Q37641644-726F6376-E8DB-4FA9-B170-4A8331729F54

P698

Q37641644-5BFC0149-50D1-4EDB-A75F-BC8C7D29FE9B

P921

Q37641644-89188259-C4D0-4A76-B379-E74C17A76470

Q37641644-B1F9DF8C-9A79-488E-BB40-A262773AE5BE

P932

Q37641644-44BDA7F4-DC80-4AF9-A6C4-9CDA2476EEF2

P356

ONCOTARGET.11202

P1433

P1476

Novel biomarkers of resistance ...... ic vesicular stomatitis virus.

@en

P2093

Eric Hastie

http://www.w3.org/2001/XMLSchema#string

Marcela Cataldi

http://www.w3.org/2001/XMLSchema#string

Megan J Moerdyk-Schauwecker

http://www.w3.org/2001/XMLSchema#string

Nury Steuerwald

http://www.w3.org/2001/XMLSchema#string

Sébastien A Felt

http://www.w3.org/2001/XMLSchema#string

Valery Z Grdzelishvili

http://www.w3.org/2001/XMLSchema#string

P2860

IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage

A diverse range of gene products are effectors of the type I interferon antiviral response

Prognostic and predictive markers in pancreatic adenocarcinoma

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

Viruses for tumor therapy

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer

A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen

Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus.

A compendium of potential biomarkers of pancreatic cancer.

Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity

P304

61601-61618

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.11202

http://www.w3.org/2001/XMLSchema#string

P407

P433

38

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27533247

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

5308675

http://www.w3.org/2001/XMLSchema#string